• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Drug half life"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-12 of 12

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      About mentioning quality of preparation and quality control of radiopharmaceuticals used in nuclear medicine procedures [3] 

      Wozniak, Greta; Georgoulias, Panagiotis; Archimandritis, Spiros; Dimakopoulos, Nikolaos; Fezoulidis, Ioannis (2006)

    • Article  

      Antiretrovirals for HIV exposure prophylaxis 

      Nikolopoulos, Georgios K.; Tsiodras, Sotirios; Bonovas, Stefanos; Hatzakis, A. (2012)
      Infection with Human Immunodeficiency Virus (HIV) remains a global public health problem. Although the epidemic has not been completely controlled, there was considerable progress in HIV prevention and treatment during the ...

    • Article  

      Antivirals used for influenza chemoprophylaxis 

      Tsiodras, Sotirios; Nikolopoulos, Georgios K.; Bonovas, Stefanos (2012)
      Current data about the role of adamantanes and neuraminidase inhibitors (NIs) in the chemoprophylaxis against influenza viruses were reviewed. We found significant evidence favouring the role of NIs in the chemoprophylaxis ...

    • Article  

      Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)
      The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...

    • Article  

      Management of leptomeningeal malignancy 

      Pentheroudakis, George; Pavlidis, Nicholas (2005)
      Leptomeningeal carcinomatosis is defined as malignant infiltration of the pia matter and arachnoid membrane. Leukaemias and lymphomas, lung, breast cancer and melanoma are the primary tumours commonly associated with ...

    • Article  

      Multicentre phase II pharmacological evaluation of rhizoxin 

      McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)
      Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

    • Article  

      Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study 

      Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, Nicholas (2002)
      We characterized the toxicity and determined the maximum tolerated dose of non-break weekly paclitaxel (Taxol) in chemotherapy-naive cancer patients, and studied pharmacokinetics of the formulation vehicle Cremophor-EL ...

    • Article  

      Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study 

      Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)
      Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...

    • Article  

      Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group 

      Briassoulis, E. Ch; Judson, Ian Robert; Pavlidis, Nicholas; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K. C.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. R. (2000)
      Purpose: To determine the maximum-tolerated dose (MTD), the principal toxicities, and the pharmacokinetics of 6-hour infusion of glufosfamide (beta-D-glucosylisophosphoramide mustard; D-19575), a novel alkylating agent ...

    • Article  

      Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies 

      Schellens, J. H. M.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, Stanley B.; Dombernowsky, P.; Paridaens, R.; Oosterom, A. T. Van; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, Nicholas; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, Cristiana; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. (2002)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...

    • Article  

      Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy 

      Pentheroudakis, George; Pappas, P.; Golfinopoulos, Vassilis; Fountzilas, George; Nikolaidou, M.; Boumba, V. A.; Vougiouklakis, T.; Nikiforidis, L.; Tzamakou, E.; Siarabi, O.; Marselos, M.; Pavlidis, Nicholas (2007)
      Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine ...

    • Article  

      Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors 

      Briassoulis, E. Ch; Pentheroudakis, George; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2004)
      Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD